Design
Review
No takes yet. Share an insight, caveat, or question.
No immediate change to RAS inhibitor prescribing; leaves open whether intrarenal distinctions affect outcomes in trials.
Braam et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: